Laddar...
CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancer
Small cell lung cancer (SCLC) is characterised by high relapse rates. Tumour-initiating cells (TICs) are responsible for drug resistance and recurrence of cancer. Rovalpituzumab tesirine (Rova-T), a potent humanised antibody–drug conjugate, selectively targets delta-like protein 3, which is highly e...
Sparad:
| I publikationen: | Br J Cancer |
|---|---|
| Huvudupphovsmän: | , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Nature Publishing Group UK
2020
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7921085/ https://ncbi.nlm.nih.gov/pubmed/33257843 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-01192-x |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|